Toxicity and response in cats with neoplasia treated with toceranib phosphate.

about

Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.Multimodal non-surgical treatment of a feline tracheal adenocarcinoma.

P2860

Q47417940-BE5CB1EF-D883-454F-89F5-D0BE8A964B63 Q54639724-F0390DCC-4387-4862-B046-30FEB31D3FE7

P2860

Toxicity and response in cats with neoplasia treated with toceranib phosphate.

Item

http://www.wikidata.org/entity/Q40793870

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Toxicity and response in cats with neoplasia treated with toceranib phosphate.

@en

type

Item

label

Toxicity and response in cats with neoplasia treated with toceranib phosphate.

@en

prefLabel

Toxicity and response in cats with neoplasia treated with toceranib phosphate.

@en

P1476

Toxicity and response in cats with neoplasia treated with toceranib phosphate

@en

P2093

Laura Blackwood

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.

Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

Prevalence of myocardial hypertrophy in a population of asymptomatic Swedish Maine coon cats

Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.

Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.

Prevalence of cardiomyopathy in apparently healthy cats.

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

P304

619-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1098612X16643124

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Harper

P577

2016-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27090289

http://www.w3.org/2001/XMLSchema#string

Toxicity and response in cats with neoplasia treated with toceranib phosphate.

about

P2860

P2860

Toxicity and response in cats with neoplasia treated with toceranib phosphate.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698